Neurotech International (ASX:NTI) has announced the appointment of Dr David Cantor to its board as a non-executive director.
Dr Cantor is a clinician, neuroscientist, program developer and a member of the company’s scientific advisory board.
He is currently the CEO and clinical director of Mind and Motion Developmental Centers of Georgia, a multidisciplinary treatment facility providing a range of diagnostic and treatment services to children and adults seeking help with neurological disorders such as autism, ADHD, traumatic brain injury and sensory processing disorders.
Neurotech is the developer of Mente Autism. It is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder (ASD).
Dr Cantor is also the CEO and managing partner of BrainDx. It is a software company that produces functional brain analytic software through computer-assisted quantitative EEG (QEEG) reports and big database measures of brain development.
“We are very privileged to have someone of Dr Cantor’s calibre join us on the board,” said Neurotech’s chairman Peter O’Connor. “His life’s work has been in the study and treatment of neurological disorders such as autism. Having served as a valued member of the Company’s Scientific Advisory Board from January 2017, we are now pleased to formally welcome him as a member of the board and look forward to an exciting new chapter ahead.”